PEN-866 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This PEN-866 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether PEN-866 can convert its Small molecule-drug conjugates profile and Top I biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | PEN-866 (query alias: PEN-866) |
|---|---|
| Modality / target | Small molecule-drug conjugates; Top I; TOP1 inhibitors |
| Highest global status | Phase 2 |
| Originator | Madrigal Pharmaceuticals, Inc. |
| Active developers | SciClone Pharmaceuticals (China) Co., Ltd, SciClone Pharmaceuticals (Holdings) Ltd., SciClone Pharmaceuticals LLC |
The MCP disease footprint includes Solid tumor, Non-Small Cell Lung Cancer, Small Cell Lung Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT04890093 | Phase 1/2 | Suspended | 64 | Primary endpoint not disclosed in English source |
| NCT03221400 | Phase 1/2 | Recruiting | 340 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
3533 - First in human phase 1/2a study of PEN-866, a Heat Shock Protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumors: Phase 1 results
Phase 1/2; n=21; evaluation: Not stated in English source. Reported fields: MTD(maximum tolerated dose) = 175 mg/m^2
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
PEN-866 addresses Solid tumor, Non-Small Cell Lung Cancer, Small Cell Lung Cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule-drug conjugates—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 2 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2020-03-19 | Tarveda Therapeutics and SciClone Pharmaceuticals International Establish Licensing Agreement for PEN-866 in Greater China | Phase 2 | US$4.0M upfront; US$75.0M milestones; US$79.0M stated total |
| 2016-09-19 | Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License Agreement for HSP90 Drug Conjugate Oncology Platform | Preclinical | US$163.0M milestones; US$249.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “HSP90-binding conjugates and combination therapies thereof”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical compositions with reduced TERT-butanol levels”. The milestone feed surfaced a patent-application signal described as “Targeted therapeutics”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Therapeutic index and off-target toxicity
- Resistance biology and biomarker-defined patient selection
- Differentiation from established and emerging standards
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-16. Counts and status fields may change as source records update.
